目的:探讨吉兰—巴雷综合征(GBS)患者治疗前肝功能损害与脑脊液蛋白水平间的关系。方法:回顾性分析2010年1月至2019年1月济宁医学院附属医院收治的242例GBS患者，男143例，女99例，年龄(50.8±15.8)岁，年龄范围为15～85岁。根据治疗前是否有肝功能损害分为肝功能损害组(n n＝27)和肝功能正常组(n n＝215)，比较两组患者谷草转氨酶(AST)、谷丙转氨酶(ALT)及脑脊液蛋白水平间的关系，分析肝功能损害组脑脊液蛋白水平与AST、ALT的相关性。n 结果:治疗前肝功能损害组ALT水平[(147.10±175.30)U/L]高于肝功能正常组[(22.97±11.81)U/L]，肝功能损害组AST水平[(102.50±103.20)U/L]高于肝功能正常组[(21.66±7.29)U/L]，差异有统计学意义(n P0.05)。肝功能损害组患者的脑脊液蛋白水平与ALT、AST浓度比较，差异无统计学意义(n P>0.05)。n 结论:GBS患者治疗前肝功能损害与脑脊液中蛋白水平比较，未发现显著相关性。“,”Objective:To investigate the association between pre-treatment liver damage and the protein levels in cerebrospinal fluid of patients with Guillain-Barré syndrome(GBS).Methods:A retrospective study was performed on 242 cases of patients with GBS who were admitted from January 2010 to January 2019, including 143 male and 99 female, aged(50.8±15.8)years old, ranging from 15 to 85 years old.According to whether there was liver function impairment before treatment, the patients were divided into the liver function impairment group(n n=27)and the normal liver function group(n n=215), and the relationship between aspartate aminotransferase(AST), alanine aminotransferase(ALT)and cerebrospinal fluid(CSF)protein levels in the two groups was compared to analyze the correlation between CSF protein levels and AST and ALT in the liver function impairment group.n Results:ALT level[(147.10±175.30)U/L]in the liver damage group before treatment was higher than that in the normal liver function group[(22.97±11.81)U/L]. The AST level[(102.50±103.20)U/L]in the liver damage group was higher than that in the normal liver function group[(21.66±7.29)U/L], and the difference was statistically significant(n P0.05). Compared with ALT and AST concentrations, CSF protein levels in patients with liver function impairment group showed no statistically significant difference(n P>0.05).n Conclusion:There is no significant correlation between liver damage before treatment and protein levels of cerebrospinal fluid in patients with GBS.